The Global Drug sales of Herceptin stood at USD 2,343.58 Millions in 2022
The indicator recorded a historical decline (CAGR) of27% between 2019 to 2022 and is expected to decline by ...
GlobalData projects the indicator to decline at a CAGR of...
Trastuzumab (Herceptin) is a humanized IgG1 kappa monoclonal antibody. It is formulated as freeze-dried powder for solution for intravenous administration and solution for subcutaneous, intravenous route of administration.
Mechanism of Action
Trastuzumab is cytotoxic to cells expressing human epidermal growth factor receptor 2. The drug inhibits the proliferation of human tumor cells that overexpress HER2. The drug acts as mediator of antibody-dependent cellular cytotoxicity. Trastuzumab binds to the HER2 (c-erbB2) proto-oncogene, an EGF receptor-like protein found in breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.
Herceptin Overview
Herceptin is marketed for several indications in oncology therapy area.
Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer, in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable, in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease, adult patients with HER2 positive early breast cancer, in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture containing the antibiotic gentamicin. The drug candidate is based on enhanze technology which is a drug delivery platform designed to increase the absorption and dispersion of biologics.
Herceptin was first approved in 1998 and is sold globally including the US, the UK, France, Germany, and Japan by F. Hoffmann-La Roche Ltd and its subsidiaries. Herceptin drug sales recorded a low-double digit Year on Year decline in 2022. Herceptin drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward